Cannabis and Eating Disorders
Limited evidence for one synthetic cannabinoid in chronic anorexia; substantial risks in eating disorder populations.
This article is for information only and is not medical advice. Talk to a doctor before using cannabis for a health condition, and do not stop or change prescribed treatment on your own.
Cannabis has a well-earned reputation for stimulating appetite, so it sounds like it should help anorexia. But eating disorders are psychiatric illnesses, not simply 'not eating enough.' The only human trial worth citing is small, short, and showed weight gain without touching the disorder itself. For bulimia and binge eating, introducing an appetite-stimulating drug makes no sense. Real risks—especially substance use comorbidity—are substantial.
Not medical advice
This article summarizes published research on cannabis and eating disorders. It is not medical advice and is not a substitute for evaluation and treatment by a qualified clinician. Eating disorders have among the highest mortality rates of any psychiatric illness. If you or someone you know is struggling, contact a physician, a specialist eating disorder service, or a crisis line. Do not use cannabis as a substitute for evidence-based treatment.
Plain-language summary
Eating disorders include anorexia nervosa (AN), bulimia nervosa (BN), binge eating disorder (BED), and avoidant/restrictive food intake disorder (ARFID). The body's endocannabinoid system plays a role in appetite, reward, and weight regulation, which is why scientists have explored whether cannabinoids might help [1][2] Strong evidence.
Cannabis is famous for increasing appetite. This makes it seem like a natural candidate for anorexia. However, the clinical evidence is small and inconsistent. The strongest study to date is a 2014 randomized controlled trial of dronabinol (pharmaceutical-grade synthetic THC) in 24 women with long-standing anorexia nervosa, which found modest weight gain over four weeks without improvement in eating-disorder thoughts or behaviors [3] Weak / limited. There are no completed randomized trials for bulimia nervosa, binge eating disorder, or ARFID No data.
Meanwhile, observational studies of people with eating disorders who use cannabis show associations with higher rates of substance use disorders and, in some cohorts, worse clinical outcomes [4][5] Weak / limited.
What probably works
No cannabinoid product is approved by the FDA, EMA, or MHRA for any eating disorder. No single cannabinoid or cannabis product meets the bar for 'probably works' in primary eating disorders.
The only established uses of cannabinoids in appetite or weight problems are in very different clinical contexts:
- Dronabinol for AIDS-related wasting: FDA-approved since 1992. Multiple controlled trials from the 1990s showed it increases appetite and weight in people with HIV/AIDS [6] Strong evidence. This does not translate to eating disorders, where appetite drive is often intact but psychological barriers to eating are severe.
- Cannabinoids for chemotherapy-induced nausea and vomiting: Moderate evidence from systematic reviews supports nabilone and dronabinol in patients undergoing cancer therapy [7] Strong evidence. Again, this is a different problem (nausea suppression) from the complex psychiatric syndrome of an eating disorder.
These regulatory approvals and evidence bases should not be extrapolated to eating disorders without new, dedicated human trials.
What might work
Dronabinol in severe, chronic anorexia nervosa. Andries et al. (2014) conducted a crossover trial in 24 women with severe, treatment-resistant anorexia nervosa (average illness duration ~17 years) [3] Weak / limited. Participants received dronabinol 2.5 mg twice daily or placebo for four weeks each. Dronabinol produced a mean weight gain of approximately 0.73 kg more than placebo. Eating-disorder psychopathology—the core problem (preoccupation with weight, shape anxiety, dietary restriction, drive for thinness)—did not improve. The trial was small, lasted only four weeks, and enrolled a highly chronic population. Results should not be generalized to adolescents, acute-onset AN, or other eating disorders.
Endocannabinoid system dysfunction in eating disorders. Neuroimaging studies show altered CB1 receptor binding in the brains of people with anorexia and bulimia compared to healthy controls, suggesting disrupted endocannabinoid signaling [2][8] Weak / limited. This is a mechanistic observation, not evidence that targeting this system will help.
CBD for comorbid anxiety. Anxiety disorders are common in people with eating disorders. Some preliminary human evidence exists for CBD in specific anxiety conditions, such as social anxiety [9] Weak / limited. However, whether treating comorbid anxiety with CBD would improve eating-disorder outcomes has not been tested No data.
What doesn't work or has weak evidence
- Recreational cannabis for anorexia nervosa. No controlled trials support it. Observational studies of people with AN who use cannabis document higher rates of comorbid depression, anxiety, and substance use disorders, with no evidence of improved eating-disorder outcomes [4][5] Weak / limited.
- Cannabis for bulimia nervosa. No randomized trials exist. Mechanistically, THC's disinhibiting effects on eating could plausibly worsen binge–purge cycles, but this has not been formally studied No data.
- Cannabis for binge eating disorder. No randomized trials. Cannabis use is associated with increased food intake in general populations, and observational data link heavy use to higher BMI over time [10] Weak / limited. Treating a binge disorder with an appetite-stimulating drug contradicts the underlying pathophysiology No data.
- Strain-specific claims (e.g., 'indica strains calm eating anxiety'). Indica and sativa labels do not reliably predict clinical effects and should not guide treatment decisions. See Indica vs Sativa Effects for details Disputed.
What we don't know
- Whether dronabinol's modest weight effect persists beyond four weeks, or whether it generalizes to adolescents, acute-onset AN, or other eating-disorder subtypes.
- Whether CBD (the non-intoxicating cannabinoid) has any role in reducing eating-disorder-related anxiety, body-image distress, or obsessive features.
- Whether cannabis use during eating-disorder recovery increases relapse risk in a causal way, or simply co-occurs with other risk factors for poor outcome.
- Whether newer cannabinoid targets (e.g., FAAH inhibitors, peripheral CB1 modulators) studied in preclinical research could help in eating disorders. No human trials exist No data.
- Interactions between cannabis and standard eating-disorder medications (SSRIs, olanzapine) in this population No data.
Comparison with standard, evidence-based treatment
Evidence-based eating disorder treatment does not include cannabis:
Anorexia nervosa: Nutritional rehabilitation, psychotherapy, and often hospitalization for the most severe cases form the foundation. Family-Based Treatment (FBT) has the strongest evidence in adolescents [11] Strong evidence. Olanzapine has modest evidence for accelerating weight restoration in adults [11] Strong evidence.
Bulimia nervosa: Cognitive Behavioral Therapy for eating disorders (CBT-E), delivered in 16–20 sessions, is first-line and has strong evidence [12] Strong evidence. Fluoxetine at 60 mg daily is the only FDA-approved medication [12] Strong evidence.
Binge eating disorder: CBT-E and interpersonal therapy have strong evidence [13] Strong evidence. Lisdexamfetamine is FDA-approved for moderate-to-severe BED [13] Strong evidence.
Against this evidence backdrop, cannabis-based approaches are, at best, experimental adjuncts in narrowly defined, highly chronic populations and are not replacements for standard care.
Risks specific to eating disorder populations
- Substance use comorbidity. People with eating disorders, especially those with the binge–purge subtype of AN or bulimia nervosa, carry elevated lifetime risk of substance use disorders. Introducing regular cannabis use is a substantive clinical risk in this group [4][5] Weak / limited.
- Psychiatric effects. Higher doses of THC can worsen anxiety, paranoia, and depersonalization. People with eating disorders often already struggle with high anxiety and dissociation Strong evidence.
- Cognitive and motivation. Heavy regular cannabis use may impair executive function and motivation, both already compromised during acute malnutrition and starvation states Weak / limited.
- Cardiovascular concerns. Severely underweight patients with anorexia often have bradycardia, low blood pressure, and QT-interval prolongation on electrocardiogram. THC causes tachycardia (increased heart rate), which is not benign in this context Weak / limited.
- Treatment engagement. Regular cannabis use is associated with poorer adherence to psychotherapy in several psychiatric populations Weak / limited.
For more on cannabis interactions with other medications, see Cannabis and Polypharmacy Risks.
Bottom line
Cannabis is not a treatment for eating disorders. The entire positive human evidence base consists of one small, four-week trial showing modest weight gain from dronabinol in long-standing anorexia nervosa—without improvement in the psychological core of the illness. For bulimia nervosa, binge eating disorder, and ARFID, there is essentially no controlled evidence. Standard care—psychotherapy, nutritional rehabilitation, and evidence-based medication when indicated—remains the correct foundation. Anyone considering cannabinoids as part of eating-disorder management should do so only under specialist supervision, with full awareness of the comorbidity risks and absence of benefit data for most eating disorders.
Sources
- Peer-reviewed Di Marzo V, Matias I. Endocannabinoid control of food intake and energy balance. Nature Neuroscience. 2005;8(5):585–589.
- Peer-reviewed Gérard N, Pieters G, Goffin K, Bormans G, Van Laere K. Brain type 1 cannabinoid receptor availability in patients with anorexia and bulimia nervosa. Biological Psychiatry. 2011;70(8):777–784.
- Peer-reviewed Andries A, Frystyk J, Flyvbjerg A, Støving RK. Dronabinol in severe, enduring anorexia nervosa: a randomized controlled trial. International Journal of Eating Disorders. 2014;47(1):18–23.
- Peer-reviewed Root TL, Pinheiro AP, Thornton L, et al. Substance use disorders in women with anorexia nervosa. International Journal of Eating Disorders. 2010;43(1):14–21.
- Peer-reviewed Bahji A, Mazhar MN. Prevalence of Cannabis Use Disorder Among Individuals with Eating Disorders: A Systematic Review and Meta-Analysis. Journal of Dual Diagnosis. 2019;15(4):287–297.
- Peer-reviewed Beal JE, Olson R, Laubenstein L, et al. Dronabinol as a treatment for anorexia associated with weight loss in patients with AIDS. Journal of Pain and Symptom Management. 1995;10(2):89–97.
- Peer-reviewed Whiting PF, Wolff RF, Deshpande S, et al. Cannabinoids for Medical Use: A Systematic Review and Meta-analysis. JAMA. 2015;313(24):2456–2473.
- Peer-reviewed Monteleone P, Piscitelli F, Scognamiglio P, et al. Hedonic eating is associated with increased peripheral levels of ghrelin and the endocannabinoid 2-arachidonoyl-glycerol in healthy humans. Journal of Clinical Endocrinology & Metabolism. 2012;97(6):E917–E924.
- Peer-reviewed Bergamaschi MM, Queiroz RH, Chagas MH, et al. Cannabidiol reduces the anxiety induced by simulated public speaking in treatment-naïve social phobia patients. Neuropsychopharmacology. 2011;36(6):1219–1226.
- Peer-reviewed Sansone RA, Sansone LA. Marijuana and body weight. Innovations in Clinical Neuroscience. 2014;11(7–8):50–54.
- Peer-reviewed Attia E, Kaplan AS, Walsh BT, et al. Olanzapine versus placebo for out-patients with anorexia nervosa. Psychological Medicine. 2011;41(10):2177–2182.
- Peer-reviewed Fluoxetine Bulimia Nervosa Collaborative Study Group. Fluoxetine in the treatment of bulimia nervosa. A multicenter, placebo-controlled, double-blind trial. Archives of General Psychiatry. 1992;49(2):139–147.
- Peer-reviewed McElroy SL, Hudson JI, Mitchell JE, et al. Efficacy and safety of lisdexamfetamine for treatment of adults with moderate to severe binge-eating disorder. JAMA Psychiatry. 2015;72(3):235–246.
How this page was made
Generation history
Drafted with AI assistance and checked by a separate automated fact-check pass. Not every article has been read by a person. See how articles are made.
Related
- Cannabis and Bipolar Disorder — Why cannabis use worsens bipolar outcomes despite subjective relief, and what the research...
- Cannabis and Polypharmacy Risks — How cannabis affects multiple-medication regimens, and which interactions are real.
- Daily Cannabis Use: Health Effects — What research shows about the health impacts of regular daily cannabis use.
- THC Dose and Anxiety — Low doses may reduce acute anxiety; higher doses increase it. Evidence is limited, risks a...